Ozempic, while originally FDA-approved for managing type 2 diabetes, is now increasingly prescribed off-label for weight loss in patients without diabetes
Novo Nordisk, the company that makes Rybelsus, Ozempic, and Wegovy, has been studying a high-dose form of semaglutide that can be taken by mouth specifically for weight loss
Bonnet, who co-authored a major clinical advisory on nutrition and GLP-1 therapy, said the key to success with GLP-1s is pairing the drugs with lifestyle changes healthier food choices and more activity
It reflects changes in gastric emptying speed, water balance, and glycogen stores as your body adjusts to different receptor stimulation patterns
They can help you develop wholesome habits that support weight management, blood sugar control, and well-being
Dermal Hypersensitivity Reaction to Semaglutide: Two Case Reports